Characteristics of circulating immune cells in HBV-related acute-on-chronic liver failure following artificial liver treatment

• Published in: BMC immunology Vol. 24; no. 1; p. 47
• Main Authors: Ju, Tao, Jiang, Daixi, Zhong, Chengli, Zhang, Huafen, Huang, Yandi, Zhu, Chunxia, Yang, Shigui, Yan, Dong
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 25.11.2023; BioMed Central; BMC
• Subjects: Acute-on-chronic liver failure; Acute-On-Chronic Liver Failure - complications; Acute-On-Chronic Liver Failure - therapy; Analysis; Artificial liver support system; Biomarkers; Care and treatment; CD4 antigen; CD8 antigen; CD8-Positive T-Lymphocytes; Control; Cytokines; Cytometry; Effector cells; Hepatitis B; Hepatitis B virus; Hepatitis B, Chronic - therapy; Hospitals; Humans; Identification and classification; Immunological memory; Immunophenotype; Immunotherapy; Liver; Liver diseases; Liver failure; Liver, Artificial - adverse effects; Lymphocytes; Lymphocytes T; Mass cytometry; Medical prognosis; Medical research; Medicine, Experimental; Memory cells; Monocytes; Mortality; Natural killer cells; Neutrophils; Pathogenesis; Patient outcomes; Peripheral blood; Prevention; Prognosis; Risk factors; China; United States > US; Acute-on-chronic liver failure; Artificial liver support system; Mass cytometry; Immunophenotype; Hepatitis B
• ISSN: 1471-2172; 1471-2172
• DOI: 10.1186/s12865-023-00579-8

Liver failure, which is predominantly caused by hepatitis B (HBV) can be improved by an artificial liver support system (ALSS). This study investigated the phenotypic heterogeneity of immunocytes in patients with HBV-related acute-on-chronic liver failure (HBV-ACLF) before and after ALSS therapy. A total of 22 patients with HBV-ACLF who received ALSS therapy were included in the study. Patients with Grade I according to the ACLF Research Consortium score were considered to have improved. Demographic and laboratory data were collected and analyzed during hospitalization. Immunological features of peripheral blood in the patients before and after ALSS were detected by mass cytometry analyses. In total, 12 patients improved and 10 patients did not. According to the immunological features data after ALSS, the proportion of circulating monocytes was significantly higher in non-improved patients, but there were fewer γδT cells compared with those in improved patients. Characterization of 37 cell clusters revealed that the frequency of effector CD8 T (P = 0.003), CD4 T (P = 0.033), CD4 T (P = 0.039), and inhibitory natural killer (NK) cells (P = 0.029) decreased in HBV-ACLF patients after ALSS therapy. Sub group analyses after treatment showed that the improved patients had higher proportions of CD4 T (P = 0.010), CD4 T (P = 0.021), and γδT cells (P = 0.003) and a lower proportion of monocytes (P = 0.012) compared with the non-improved patients. Changes in effector CD8 T cells, effector and memory CD4 T cells, and inhibitory NK cells are associated with ALSS treatment of HBV-ACLF. Moreover, monocytes and γδT cells exhibited the main differences when patients obtained different prognoses. The phenotypic heterogeneity of lymphocytes and monocytes may contribute to the prognosis of ALSS and future immunotherapy strategies.